|
Fluofarma, one of NDI’s partner companies, has developed a technology that enables identification of lead compounds based on their biological effects on identified targets, at the earliest stages of drug discovery.
Technology:
The proprietary technology, based on automated flow cytometry, combines cell-based assays with large–scale analysis. It allows a functional analysis of several molecular events simultaneously in single cells.
Services for drug discovery:
- Functional target validation
- Library screening for chemical entities, crude extracts, proteins or gene collections
- Lead selection and optimization
- Compound profiling and mechanism of action studies
Key Features:
- Functional measuring: Assessment of molecular events in living neurons
- Multiplexing: Measurement of up to 5 parameters simultaneously in single cells
- Large-scale: 2000 wells tested per day with 2500 cells analyzed individually per well
|
